Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 9.800 +0.010 (+0.10%) Streaming Delayed Price Updated: 12:14 PM EDT, Jul 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Travere Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low September 21, 2023 It's now up to the FDA whether the company's key drug remains on the market. Via Investor's Business Daily Exposures Product Safety Stocks That Hit 52-Week Lows On Thursday September 21, 2023 During the session on Thursday, 461 stocks hit new 52-week lows. Via Benzinga Analyst Ratings for Travere Therapeutics September 06, 2023 Via Benzinga The Latest Analyst Ratings for Travere Therapeutics August 18, 2023 Via Benzinga Gold Down Over 1%; FedEx Shares Rise On Earnings Beat September 21, 2023 U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... Via Benzinga Topics Stocks Exposures US Equities Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected September 21, 2023 U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... Via Benzinga Topics Stocks Exposures US Equities Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? September 21, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) announced Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session September 21, 2023 Via Benzinga Earnings Scheduled For August 3, 2023 August 03, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. Via Benzinga Expert Ratings for Travere Therapeutics July 18, 2023 Via Benzinga Analyst Ratings for Travere Therapeutics June 07, 2023 Via Benzinga 11 Analysts Have This to Say About Travere Therapeutics May 22, 2023 Via Benzinga Recap: Travere Therapeutics Q1 Earnings May 04, 2023 Via Benzinga Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session September 21, 2023 U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know September 19, 2023 Via Benzinga EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug September 08, 2023 Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way. Via Benzinga 3 Small-Cap Stocks That Could Be Big-Time Winners July 22, 2023 These stocks come with significant risks. But they could generate huge returns over time. Via The Motley Fool Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan July 21, 2023 Travere Therapeutics shares have lost nearly 30% since early May. Via Talk Markets Earnings Outlook For Travere Therapeutics May 03, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 July 21, 2023 Via Benzinga Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation July 17, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session July 17, 2023 Via Benzinga Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire July 05, 2023 Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. Via Investor's Business Daily 3 Biotech Stocks That Could Skyrocket in the Next 12 Months June 07, 2023 These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. Via InvestorPlace 3 Biotech Stocks With Blockbuster Potential May 24, 2023 Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 May 22, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session May 02, 2023 Via Benzinga Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday May 02, 2023 U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session. Via Benzinga Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test May 02, 2023 Travere was testing a treatment for FSGS, a condition that causes kidney scarring. Via Investor's Business Daily Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward May 02, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) announced Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.